Tag: Biocon
Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...
The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period
World Cancer Day: Dr Devi Shetty & Kiran Mazumdar Shaw inaugurate...
The unit will boost of CAR-T Cell Therapy & Immunotherapy and has proficient medical staff including of haemato-oncologists, BMT physicians and nursing staff.
Shreehas Tambe appointed as MD & CEO of Biocon Biologics
Mr Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics
Biocon ranks No. 8 in ‘Global Top Employers’ by Science magazine
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Biocon Biologics subsidiary enters Malaysia Book of Records
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia
US FDA issues observations for Biocon Biologics sites
At the conclusion of these inspections, the agency has issued Form 483s with 11 observations each for the two sites in Bengaluru and 6 observations for the Malaysia site
CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics
The target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases
Pharma industry reiterates its commitment to US$ 130 billon by 2030
Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance
Biocon Biologics & Serum Institute Life Sciences announce strategic alliance
BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets. SILS to receive ~15% stake in BBL at a post-money valuation of ~$4.9 billion......................
Syngene clocks 12% growth in FY21 revenue at Rs. 2,184 crore
Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year......................